CaMKII inhibitor KN-62 blunts tumor response to hypoxia by inhibiting HIF-1α in hepatoma cells

Korean Journal of Physiology and Pharmacology

Volumn 14, Issue 5, 2010, Pages 331-336

  Lee, Kyoung Hwa ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

CaMKII; Hepatocellular carcinoma; HIf1 ; Hypoxia; KN 62

Indexed keywords

1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; GENE EXPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; HYPOXIA; LIVER CELL CARCINOMA; PROTEIN STABILITY; PROTEIN SYNTHESIS; TREATMENT RESPONSE;

EID: 78649378265     PISSN: 12264512     EISSN: None     Source Type: Journal    
DOI: 10.4196/kjpp.2010.14.5.331     Document Type: Article

References (39)

1. Hockel M, Vaupel P. Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects. J Natl Cancer Inst. 2001;93:266-276.
2. Semenza G, Wang G. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12:5447-5454.
3. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O-2-regulated prolyl hydroxylation. Science. 2001;292:468-472.
4. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA. 1998;95:7987-7992.
5. Berra E, Ginouvès A, Pouysségur J. The hypoxia-inducible- factor hydroxylases bring fresh air into hypoxia signalling. EMBO Reports. 2006;7:41-45.
6. Pugh C, O'Rourke J, Nagao M, Gleadle J, Ratcliffe P. Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit. J Biol Chem. 1997;272:11205.
7. Arany Z, Huang L, Eckner R, Bhattacharya S, Jiang C, Goldberg M, Bunn H, Livingston D. An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci USA. 1996;93:12969.
8. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza G, Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem. 2002;277:27975.
9. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT. Regulation of Hypoxia-Inducible Factor 1alpha Expression and Function by the Mammalian Target of Rapamycin. Mol Cell Biol. 2002;22:7004-7014.
10. Ducibella T, Schultz RM, Ozil JP. Role of calcium signals in early development. Seminars in Cell & Developmental Biology. 2006;17:324-332.
11. Zayzafoon M. Calcium/calmodulin signaling controls osteoblast growth and differentiation. J Cell Biochem. 2006;97:56-70.
12. 2+/ Calmodulin Dependent Protein Kinase II Inhibitor on Cell Cycle. Biochem Biophys Res Commun. 1994;199:241-248.
13. 2+/CaM kinase). Cell Growth Differ. 1995;6:1063-1070.
14. Hui AS, Bauer AL, Striet JB, Schnell PO, Czyzyk-Krzeska MF. Calcium signaling stimulates translation of HIF-1 alpha during hypoxia. FASEB J. 2006;20:466-475.
15. Youn H-D, Chatila TA, Liu JO. Integration of calcineurin and MEF2 signals by the coactivator p300 during T-cell apoptosis. EMBO J. 2000;19:4323-4331.
16. Meissner JD, Umeda PK, Chang KC, Gros G, Scheibe RJ. Activation of the β myosin heavy chain promoter by MEF-2D, MyoD, p300, and the calcineurin/NFATc1 pathway. J Cell Phys. 2007;211:138-148.
17. Rhun YL, Kirkland JB, Shah GM. Cellular Responses to DNA Damage in the Absence of Poly (ADP-ribose) Polymerase. Biochem Biophys Res Commun. 1998;245:1-10.
18. Ermak G, Davies KJ. Calcium and oxidative stress: from cell signaling to cell death. Mol Immunol. 2002;38:713-721.
19. Virag L, Scott GS, Antal-Szalmas P, O'Connor M, Ohshima H, Szabo C. Requirement of intracellular calcium mobilization for peroxynitrite-induced poly (ADP-ribose) synthetase activation and cytotoxicity. Mol Pharmacol. 1999;56:824-833.
20. Martin-Oliva D, Aguilar-Quesada R, O'Valle F, Muñoz-Gámez JA, Martínez-Romero R, García del Moral R, Ruiz de Almodóvar JM, Villuendas R, Piris MA, Oliver FJ. Inhibition of poly (ADP-Ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Research. 2006;66:5744-5756.
21. Martínez-Romero R, Martínez-Lara E, Aguilar-Quesada R, Peralta A, Oliver FJ, Siles E. PARP-1 modulates deferoxamine-induced HIF-1alpha accumulation through the regulation of nitric oxide and oxidative stress. J Cell Biochem. 2008;104:2248-2260.
22. Martínez-Romero R, Cañuelo A, Martínez-Lara E, Oliver FJ, Cárdenas S, Siles E. Poly (ADP-ribose) polymerase-1 modulation of in vivo response of brain hypoxia-inducible factor-1 to hypoxia/reoxygenation is mediated by nitric oxide and factor inhibiting HIF. J Neurochem. 2009;111:150-159.
23. Elser M, Borsig L, Hassa PO, Erener S, Messner S, Valovka T, Keller S, Gassmann M, Hottiger MO. Poly (ADP-Ribose) polymerase 1 promotes tumor cell survival by coactivating hypoxia-inducible factor-1-dependent gene expression. Molecular Cancer Research. 2008;6:282-290.
24. Chun YS, Choi E, Yeo EJ, Lee JH, Kim MS, Park JW. A new HIF-1 alpha variant induced by zinc ion suppresses HIF-1-mediated hypoxic responses. J Cell Sci. 2001;114:4051-4061.
25. Lee KH, Li M, Michalowski AM, Zhang X, Liao H, Chen L, Xu Y, Wu X, Huang J. A genomewide study identifies the Wnt signaling pathway as a major target of p53 in murine embryonic stem cells. Proceedings of the National Academy of Sciences. 2010;107:69-74.
26. Shin HW, Cho CH, Kim TY, Park JW. Sunitinib deregulates tumor adaptation to hypoxia by inhibiting HIF-1alpha synthesis in HT-29 colon cancer cells. Biochem Biophys Res Commun. 2010;398:205-211.
27. Lang KJD, Kappel A, Goodall GJ. Hypoxia-inducible Factor-1alpha mRNA Contains an Internal Ribosome Entry Site That Allows Efficient Translation during Normoxia and Hypoxia. Mol Biol Cell. 2002;13:1792-1801.
28. Arsham AM, Plas DR, Thompson CB, Simon MC. Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1 alpha nor sufficient for HIF-1-dependent target gene transcription. J Biol Chem. 2002;277:15162-15170.
29. Bootman MD, Collins TJ, Peppiatt CM, Prothero LS, MacKenzie L, De Smet P, Travers M, Tovey SC, Seo JT, Berridge MJ, Ciccolini F, Lipp P. Calcium signalling - an overview. Seminars in Cell & Developmental Biology. 2001;12:3-10.
30. Howe CJ, LaHair MM, McCubrey JA, Franklin RA. Redox Regulation of the Calcium/Calmodulin-dependent Protein Kinases. J Biol Chem. 2004;279:44573-44581.
31. 2+/calmodulin kinase-dependent activation of hypoxia inducible factor 1 transcriptional activity in cells subjected to intermittent hypoxia. J Biol Chem. 2005;280:4321-4328.
32. 2+ signaling, prolyl hydroxylases, and mTOR. J Cell Phys. 2008;217: 674-685.
33. Westra J, Brouwer E, Bos R, Posthumus MD, Meer BD-VD, Kallenberg CGM, Limburg PC. Regulation of Cytokine-Induced HIF-1alpha; Expression in Rheumatoid Synovial Fibroblasts. Annals of the New York Academy of Sciences. 2007;1108:340-348.
34. Westra J, Brouwer E, Bouwman E, Meer BD-vd, Posthumus MD, Leeuwen MAv, Limburg PC, Ueda Y, Kallenberg CGM. Role for CaMKII Inhibition in Rheumatoid Arthritis. Annals of the New York Academy of Sciences. 2009;1173:706-711.
35. Westra J, Brouwer E, van Roosmalen IA, Doornbos-van der Meer B, van Leeuwen MA, Posthumus MD, Kallenberg CG. Expression and regulation of HIF-lalpha in macrophages under inflammatory conditions; significant reduction of VEGF by CaMKII inhibitor. BMC Musculoskelet Disord. 2010;11:61.
36. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: Worldwide incidence and trends. Gastroenterology. 2004;127:S5-S16.
37. Jee SH, Ohrr H, Sull JW, Samet JM. Cigarette Smoking, Alcohol Drinking, Hepatitis B, and Risk for Hepatocellular Carcinoma in Korea. J Natl Cancer Inst. 2004;96:1851-1856.
38. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 2005;5:876-885.
39. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, Haga N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Science. 2003;94:15-21.